Middle East and Africa Cancer Hormone Therapy Market (2021–2031)

The Middle East and Africa cancer hormone therapy market size is expected to reach US$ 1,468.2 million by 2031 from US$ 841.3 million in 2024. The market is estimated to record a CAGR of 8.3% from 2025 to 2031.

Executive Summary and Middle East and Africa Cancer Hormone Therapy Market Analysis:

Hormone therapies are recognized as essential treatments for hormone-sensitive cancers such as breast and prostate cancer, especially as awareness of these conditions grows among clinicians and patients. The market is driven by expanding oncology facilities, growing adoption of international treatment protocols, and increasing public health initiatives aimed at early cancer detection. Partnerships between governments, private healthcare providers, and international pharmaceutical companies are accelerating the availability and integration of hormone therapies across the region.

Unequal access to oncology care between urban centers and rural areas limits the reach of hormone therapy in several countries. Additionally, high treatment costs and fragmented reimbursement policies hinder adoption, particularly in low- and middle-income nations. Regulatory variations and the limited availability of trained oncology specialists in some areas restrict market growth. Despite these barriers, the region shows potential for expansion through investment in cancer care infrastructure, professional training programs, and collaborative initiatives with global pharma players to improve accessibility and standardize care.

Middle East and Africa Cancer Hormone Therapy Market - Strategic Insights:

Middle East and Africa Cancer Hormone Therapy Market Segmentation Analysis:

Key segments that contributed to the derivation of the Middle East and Africa cancer hormone therapy market analysis are drug class, cancer type, route of administration, and sales channel.

• By drug class, the cancer hormone therapy market is segmented into GnRH analogs, GnRH antagonists, androgen receptor antagonists, aromatase inhibitors, selective estrogen receptor modulators, estrogen receptor antagonists, thyroid hormone therapy, and others. The GnRH analogs segment dominated the market in 2024.
• By cancer type, the cancer hormone therapy market is segmented into breast cancer, prostate cancer, endometrial cancer, ovarian cancer, thyroid cancer, and others. The breast cancer segment dominated the market in 2024.
• By route of administration, the cancer hormone therapy is segmented into oral, injectable, and implantable. The oral segment dominated the market in 2024.
• By sales channel, the cancer hormone therapy market is segmented into hospitals, cancer treatment centers, specialty clinics, and retail pharmacies. The hospitals segment dominated the market in 2024.

Middle East and Africa Cancer Hormone Therapy Market Drivers and Opportunities:

Increasing Occurrence of Hormone-Driven Tumors

The incidence of hormone-responsive cancers, particularly breast and prostate cancers, is rising across the Middle East and Africa due to demographic shifts, urbanization, and lifestyle changes. Countries such as Saudi Arabia, Egypt, and the UAE report increasing breast cancer cases, often diagnosed at younger ages, while prostate cancer prevalence is notably high in South Africa and North African countries. Delayed diagnosis and limited awareness exacerbate disease burden, highlighting a growing need for systemic therapies such as hormone-blocking agents and androgen deprivation therapies.

Healthcare infrastructure is improving unevenly across the region, with major urban centers—Riyadh, Cairo, and Johannesburg—offering comprehensive oncology services, including access to oral and injectable hormone therapies. Rural and semi-urban areas face shortages of endocrinology-trained oncologists and limited access to diagnostic tools like hormone receptor testing and PSA screening. This disparity drives cross-referrals within countries and to regional hubs for management of advanced-stage hormone-sensitive cancers.

National cancer strategies and government-led initiatives are beginning to target early detection and treatment standardization. Egypt and Morocco have launched breast cancer awareness campaigns and subsidized endocrine therapies, while Gulf Cooperation Council (GCC) states include hormone therapies in national formularies. As awareness rises and diagnostic capacity improves, the prevalence of hormone-responsive cancers is creating sustained demand for first-line and maintenance hormone therapies across the region.

Surge in the Use of Combination Therapies

The use of combination therapies, pairing hormone agents with targeted therapies or chemotherapy, is accelerating across the Middle East and Africa. In breast cancer, CDK4/6 inhibitors combined with aromatase inhibitors are gaining uptake in countries like the UAE, Qatar, and Saudi Arabia, driven by reimbursement expansion and regional oncology guidelines. Similarly, advanced prostate cancer management leverages androgen deprivation therapy alongside novel androgen receptor inhibitors, reflecting alignment with global treatment protocols.

Regional centers of excellence are enhancing adoption through multidisciplinary care pathways. Leading oncology hospitals in Johannesburg, Cairo, and Riyadh implement tumor boards that integrate molecular profiling and imaging to guide combination therapy decisions. These centers pilot sequencing strategies, such as adding PARP inhibitors for BRCA-mutated breast and prostate cancers, offering more personalized and effective regimens while building local evidence for broader adoption.

Policy shifts, including national insurance coverage and clinical guideline updates, are reinforcing combination therapy uptake. In North Africa, governments are negotiating lower-cost generic options for hormone-targeted regimens, while Gulf countries leverage public-private partnerships to subsidize innovative agents. Patient preference for treatments that improve survival without increasing toxicity drives demand, positioning the market for steady growth with an emphasis on integrated, multi-agent treatment strategies.

Middle East and Africa Cancer Hormone Therapy Market Size and Share Analysis:

The Middle East and Africa cancer hormone therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within drug class, cancer type, route of administration, and sales channel, highlighting their respective contributions to overall market performance.

By drug class, the GnRH analogs subsegment dominated the market in 2024. Their proven efficacy in hormone-dependent cancers, widespread clinical adoption, established safety profile, and ability to effectively suppress gonadotropin release make them a cornerstone of endocrine-based cancer therapies.

Per cancer type, the breast cancer subsegment dominated the market in 2024, driven by the high global prevalence of breast cancer, increasing awareness and screening programs, strong reliance on hormone-based treatments, and continuous advancements in targeted and combination therapies.

By route of administration, the oral subsegment dominated the market in 2024. Oral therapies are preferred due to their ease of administration, improved patient compliance, convenience for long-term treatment, reduced need for hospital visits, and growing availability of effective oral oncology drugs.

Per sales channel, the hospitals subsegment dominated the market in 2024. Hospitals remain the primary distribution channel as they offer comprehensive cancer care, access to specialized oncology pharmacists, advanced treatment infrastructure, and integrated diagnostic and therapeutic services, ensuring efficient delivery of cancer medications.

Middle East and Africa Cancer Hormone Therapy Market Report Highlights:

Middle East and Africa Cancer Hormone Therapy Market Report Coverage and Deliverables:

The "Middle East and Africa Cancer Hormone Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Middle East and Africa Cancer Hormone Therapy market size and forecast at regional and country levels for all the key market segments covered under the scope
• Middle East and Africa Cancer Hormone Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Middle East and Africa Cancer Hormone Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Middle East and Africa Cancer Hormone Therapy market
• Detailed company profiles, including SWOT analysis

Middle East and Africa Cancer Hormone Therapy Market Geographic Insights:

The geographical scope of the Middle East and Africa Cancer Hormone Therapy market report is divided into: Saudi Arabia, the United Arab Emirates, Kuwait, Bahrain, Qatar, Oman, Turkiye, South Africa, Egypt, Nigeria, Algeria, and the Rest of MEA. South Africa held the largest share in 2024.

South Africa dominates the market due to its comparatively advanced healthcare infrastructure and established oncology ecosystem. The country has specialized cancer centers and academic hospitals that routinely incorporate hormone therapies into standardized treatment protocols for hormone-responsive cancers. Early detection programs and structured clinical guidelines have increased the adoption of hormone therapy as a critical component of comprehensive cancer management.

South Africa’s pharmaceutical landscape, which includes domestic and multinational players, supports broad access to established and innovative hormone therapies. Collaborative research initiatives and clinical trials conducted locally enhance the country’s capacity to adopt new treatments and improve patient outcomes. However, challenges remain in bridging disparities between the private and public healthcare sectors, as access to advanced hormone therapies can be limited outside major urban centers. Policy efforts and investments aimed at improving healthcare equity, strengthening oncology training, and increasing the availability of hormone treatments are expected to reinforce South Africa’s leadership in the region and drive market growth across neighboring countries.

Middle East and Africa Cancer Hormone Therapy Market Research Report Guidance:

• The report includes qualitative and quantitative data in the Middle East and Africa cancer Hormone therapy market across by drug class, cancer type, route of administration, sales channel, and geography.

• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Middle East and Africa Cancer Hormone Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Middle East and Africa Cancer Hormone Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Middle East and Africa Cancer Hormone Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.

• Chapters 7 to 11 cover Middle East and Africa Cancer Hormone Therapy market segments by drug class, cancer type, route of administration, sales channel, and geography across Saudi Arabia, the United Arab Emirates, Kuwait, Bahrain, Qatar, Oman, Turkiye, South Africa, Egypt, Nigeria, Algeria, and Rest of MEA. They cover the market revenue, forecast, and factors driving the market.

• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Middle East and Africa Cancer Hormone Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

Middle East and Africa Cancer Hormone Therapy Market News and Key Development:

The Middle East and Africa Cancer Hormone Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Middle East and Africa cancer hormone therapy market are:

• In January 2026, The Pfizer Foundation announced that it would expand its breast cancer initiative with a new three-year, US$ 10 million investment to improve breast cancer diagnosis, treatment, and care in Kenya and Ethiopia — part of its ongoing efforts to address disparities in breast cancer outcomes in sub-Saharan Africa, including support for access to therapies used in hormone receptor-positive breast cancer management.
• In April 2025, Hikma Pharmaceuticals PLC announced that it signed an exclusive licensing agreement with pharma& GmbH to commercialise rucaparib (Rubraca) in the Middle East and North Africa (MENA) region, enhancing its oncology portfolio across the region to include a targeted cancer therapy that complements broader treatment strategies (including hormone-related cancers by improving overall oncology care availability).

Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• American Association for Cancer Research (AACR)
• National Cancer Institute (NCI)
• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• Company Websites
• Company Annual Reports
• Company Investor Presentations